There is much evidence to suggest that the treatment of hypertension reduces the risk of cardiovascular diseases and that it is cost-effective in most patients. However, the effectiveness of treatment relies on compliance and maintenance of treatment. Each pharmacological agent differs in terms of side effects. The existence of side effects can result in poor compliance and switching between treatments. A number of studies have reported high discontinuation rates for anti-hypertensive therapies. This potentially imposes costs on the health service.
Introduction
There is considerable evidence that the effective treatment of hypertension reduces the risk of cardiovascular disease.
1,2 Treatment for hypertension is also cost-effective in virtually all patient populations and circumstances with a variety of drugs. Effective treatment of hypertension does not, however, negate completely the risk of heart disease. Moreover, risk reduction will only be attained if treatment management is maintained and this is not always the case. A number of hypertensive treatments are accompanied by adverse reactions in certain individuals and there can be interactions amongst some agents. There are currently five main classes of pharmacological interventions used as first-line treatments for hypertension; ACE inhibitors, beta-blockers, calcium antagonists, diuretics and the newly introduced Angiotensin II antagonists. All differ in their pharmacological effects and side effect profile, consequently, treatment management is not straightforward. Subsequently, treatment compliance may be poor, and switching across different forms of treatment may occur if the side effects are persistent.
A number of studies have indeed reported relatively high treatment discontinuation rates. Two randomised clinical trials studying mild hypertension reported withdrawal rates due to side effects of 43% for a group of diuretic patients and 42% for a The aim of this study is to use the MEDIPLUS data set to consider the cost arising from switching and discontinuation of therapy. The analysis will assess the resource costs in terms of extra GP visits and hospitalisations arising from individuals switching and discontinuing treatments.
The total costs of hypertension were estimated to be around £76.5 m per annum, of which £26.9 m can be attributed to patients who switch or discontinue therapy.
group of beta-blocker patients after 5 years. 3 A recent study, considering new therapy initiation within hypertensives, found discontinuation rates were around 60% for the four most widely prescribed classes of drug within the first 6 months of initiation. 4 This latter study utilised the longitudinal data recorded by the MEDIPLUS data set to assess the issue of discontinuation. Information on switching was also recorded.
Using the same data set as Jones et al, 4 the objective of this study is to consider the resource costs arising from treatment discontinuation and prescription switching. The primary aim is to attach a resource cost to the discontinuation of hypertensive treatment. A secondary aim is to estimate the cost of switching across differing forms of hypertensive prescription treatments.
Methods
The methodology is empirically driven. Data were drawn from the MEDIPLUS database consistent with the earlier Jones et al study. 4 The MEDIPLUS data set holds diagnostic and medication information on 1.2 million patients across 500 general practitioners (156 GP practices) throughout the UK. The database details patient primary care, including prescriptions as well as including read coded information on hospital admissions and specialist referrals. The prescription medication information is linked to diagnosis. The data are held for individual patient records which are recorded in chronological order forming a longitudinal database for individual patients for the period of time that they remain within a single GP practice. In the UK there is relatively little movement of patients across GP practices, therefore the MEDIPLUS data represents a comprehensive record of primary care for individual patients through time. Only patients who continued to consult their GP throughout the study period were included within the study. Individuals who died or were lost to follow up during the study period were excluded. The regional distribution of the GP practices is generally representative of the UK as a whole, with the exceptions that there are a higher proportion of younger physicians and Scotland is under-represented.
Subjects for the study, as noted above, were defined in a consistent manner to the earlier Jones et al study. 4 Data were drawn from the MEDIPLUS system covering a 26-month period relating to new patients who had been both diagnosed with hypertension through the use of ICD-90M codes 401-405 and prescribed at least one anti-hypertensive agent belonging to one of the four hypertensive therapeutic classes (ie, ACE inhibitors, beta-blockers, calcium antagonists and diuretics). The period covered by the study was from 1st October 1992 through to the 31st December 1994. Individuals were identified as new hypertensives any time between October 1992 and September 1993. All cases were followed through to December 1994. Patients were also defined to be aged 40 or over at their start date as the incidence of hypertension was held to be extremely low in the under 40 year olds based on the findings that prevalence for this group was less than 5 per 1000. 4 This gave information on the incidence of new treatment for anti-hypertensives in 7741 cases.
Data collected related to the specific prescriptions for hypertension, the class of the prescribed agent, the number of primary care consultations, hospital referrals and the speciality referred to. Data on prescriptions included information on co-prescription and details on the degree of discontinuing of prescription and switching to other agents. Within each therapeutic class of hypertensive therapy the monthly discontinuation rate was analysed for a period of 7 months.
The primary aim of the analysis was to estimate the excess costs of discontinuing treatment and switching across treatment agents. To calculate these excess costs we had to classify the number of patients who discontinued treatment in the database. Patients were categorised as either individuals who continued with initially prescribed medication or treatment discontinuers based on their status at the end of the 26-month period. It was assumed, however, that all treatment discontinuation would occur within the first 6 months. This assumption is consistent with the finding by Jones et al 4 that 6-month discontinuation rates were between 50-60% for all four drug classes. The discontinuation rates in that study were comparable to the discontinuation rates in the MRC study at the end of 5 years. Table 1 outlines the percentages continuing, discontinuing, and switching drug therapy within 6 months of initiation for each individual drug class. As can be seen there is little variation although diuretics had the lowest percentage of individuals continuing on initial therapy (47%) over the 6-month period.
All patients who switched agents were classified as a sub-group of the treatment discontinuation population. Approximately 35% of all individuals who discontinued their initial treatment therapy were classified as switching treatment. The consistent assumption was made that for these cases all switching across agents would occur within the first 6 months. This assumption was adopted as analysis of the raw data indicated that the vast majority of switching took place within this period.
Individuals who discontinued initial therapy and those who switched therapy were identified through the database. The health care utilisation of discontinuers and switchers, in terms of primary and secondary care recorded, was then compared to the health care utilisation of those patients who continued on initially prescribed agents throughout the length of the follow-up period. The excess health care utilisation of treatment discontinuers and individuals who switched treatment was then identified directly from the MEDIPLUS database. To calculate the excess rate of health care utilisation, the utilisation rate was calculated for the discontinuers and the treatment switching sub-group as was the health care rate for those individuals in the data set who continued on medication throughout the study period. The excess health care utilisation rate was taken as the difference between the treatment discontinuers and those individuals who continued on initial medication (and the difference between the switching sub-group and the continuing medication population). These excess rates were calculated for GP consultations and for hospitalisations. The excess rates were calculated for the total study population as well as for five separate age groups; 40-49, 50-59, 60-69, 70-79 and over 80. It was additionally assumed that one GP visit would be associated with switching, which represented the excess primary care resource utilisation of switching. Co-prescription costs were also calculated.
Once the excess treatment volumes were estimated from the MEDIPLUS data set the excess cost could be calculated by assigning unit costs to these volumes. Prescription costs for the various agents were provided by IMS data. Each pharmaceutical agent was allocated a price based on a weighted average cost where the weights were based on the dosage and proportion of prescription items dis- pensed for that specific agent. These costs are given in Table 2 for each of the individual agents within the five classes of hypertensive therapy considered. The unit costs of a GP visit were estimated at £10 5 and the average unit cost of the various hospitalisations experienced by the identified individuals was taken from a sample of Extra Contractual Referral prices based on a population of 200 Hospital Trusts. There were a total of 10 referred types of hospitalisation and the unit average costs are given in Table 3 .
Results
To ensure we were comparing similar populations we tested for a difference in mean referral rates to GPs or hospitals in the continuer and discontinuer populations prior to start of hypertension therapy initiation for a random sample of 260 patients; ie, approximately 5% of all cases. The mean daily consultation rates were calculated for the two population groups. For GP consultations these were 0.0121 for the continuers and 0.0368 for the discontinuers and these were found not to be significantly different at the 1% level. The mean daily consultation rates for hospitalisations in the two groups were 0.0005 and 0.0009 respectively and again were not significantly different from each other at the 1% level. Table 4 presents the basic results of the study for the within sample population excess costs at an individual level of analysis for a newly diagnosed individual with hypertension who is initially prescribed a first-line agent and who subsequently discontinues this medication. The excess costs vary across the therapies and the individual age groups. In the majority of age groups discontinuers had higher health care resource use, and therefore expenditure, than those individuals who maintained their initially prescribed medication. Although in most instances these savings were relatively small. In some cases there were resource savings associated with discontinuation of initial therapy, for example in the 40-49 age group whose initial prescription was a diuretic. Whether these savings represent an overall benefit or not is undetermined, as there is no information on health status available in the data set. Table 5 presents the aggregate burden of illness for hypertension across the sample period of 26 months, utilising the assumptions outlined above. On this basis the 26-month burden is £166 m. If this aggregate burden were re-calculated on a per annum basis the total cost of illness would be £76.5 m. The largest single component of expenditure being the drug costs arising from continuing therapy patients. As noted above, however, the health care costs arising from hospitalisations and GP visits are higher for the discontinuers than the continuers. Although switchers are a sub-group of the discontinuers we have highlighted their GP costs and drug costs. As expected the drug costs are higher than those of the discontinuers.
The comparison of continuers and discontinuers as based on this aggregate analysis may be slightly misleading, however, as we know that there are more continuers than discontinuers. In other words, the per capita rates of health care utilisation and drug usage may be different. This is considered in Table 6 where the data presented in Table 5 is converted into the per capita rates relating to the 26-month study period. No cost is attributed to switch- ers for health care as this is incorporated within the discontinuers costs; ie, the cost of hospitalisation or GP visits for switchers is the same as for discontinuers at an individual level. However, as can be seen switchers have a much higher drug cost per capita than discontinuers. Indeed the switchers drug costs per capita are slightly higher than the continuers drug cost per capita. The conclusion being that switching appears to be consistent with a move onto more costly therapy on average. Using a weighted average of the population of discontinuers and switchers we calculated a per capita cost of noncontinuation of initial treatment therapy as being £224. While this is less than the per capitation cost of continuing therapy, when this population of discontinuers is disaggregated into the sub-groups of pure discontinuation and switchers, it can be seen that on average switching is more costly at the individual level. So for the 35% of the sample population classified as switchers, the per capita treatment costs were in excess of the treatment costs for those classified as continuers by some £56 which is 20% more expensive (ie, £336-£280) over a 26-month period.
Discussion
The analysis of a sample of 7741 hypertensive patients over a 26-month period suggested a total annual UK cost illness of approximately £76.5 m. This is an incidence-based figure, derived from newly-diagnosed hypertensive patients.
It is also based, given the limitations of the data used, on a limited set of assumptions. The most important of which is that all discontinuation and switching of therapy occurs within 6 months of therapy initiation. The data also allowed examination of the relative treatment costs associated with therapy continuation, discontinuation and switching.
Overall, perhaps unsurprisingly, the greatest cost was attributable to patients who continued on initial therapy throughout the 26-month study period. Within this group the cost was dominated by drug therapy costs. However, analysis based on rates per capita indicate that individuals who switched away from initial therapy had an excess cost of £56 per patient per year, representing a 20% increase over those individuals who continued on original therapy. Discontinuers were shown to be the least costly group, due almost entirely to the lack of drug costs. Once again, there were hidden excess costs with resource implications within this total figure as GP and hospital utilisation costs in both these groups were above those for continuing on the original therapy.
It is important to note however, that our findings have been restricted to a costs analysis of continuation, discontinuation and switching. The results show that almost one-third of the burden arising from the treatment of incident hypertensives is associated with switching and discontinuation of initial therapy. The inference being that these excess costs could be reduced if the anti-hypertensive therapy chosen could provide the efficacy and tolerability to ensure patients continue on treatment. The study is not able, given data restrictions, to convey the treatment benefits of reduced cardiovascular morbidity and mortality, arising from the effective treatment of hypertension.
There are obvious benefits to providing effective treatment which is well tolerated first time. We have estimated that an excess of £26.9 m per annum is associated with switching and discontinuation. With the four major classes studied in this analysis, continuation rates were very similar, resulting in a similar level of switching, discontinuation and excess costs. The main reasons for the switch from initial therapy is either lack of anti-hypertensive efficacy or unaccepable side effects experienced by the patients. From many independent studies, levels of anti-hypertensive efficacy amongst these therapeutic groups are very similar. One variable however, which is known to play a significant role in the switching of patients, is side effects and drug tolerability. This leaves us with the anticipation that drugs with comparable anti-hypertensive efficacy combined with significantly fewer side effects, through improved tolerability, will aid compliance and help reduce the £26.9 m burden imposed by switching and discontinuation. Equally, by aiding compliance, the number of true discontinuers may also be reduced further, thus reducing the long term cardiovascular consequences of uncontrolled hypertension.
